DEVELOPMENT SITE ONLY
Please use current guidelines available on the UHNM intranet for patient treatment
Please use current guidelines available on the UHNM intranet for patient treatment
INDICATIONS
- Management of cardiac failure after acute myocardial infarction (MI)
- see Acute myocardial infarction guideline
PREPARATIONS
- Dopamine hydrochloride 40 mg/mL in 5 mL ampoules (200 mg)
- Ampoules must be clear, colourless or pale yellow
- if solution is darker than slightly yellow, or discoloured, do not use
DILUENTS
- Sodium chloride 0.9% or glucose 5%
- Dopamine is inactivated by sodium bicarbonate 5% and alkaline solutions
ADMINISTRATION
- Use dopamine only in critical care and in the coronary care unit
- It is strongly advised to administer dopamine through a central line
- Give dopamine peripherally only on the advice of a consultant
- use a large vein high up in a limb, preferably the arm
- in order to reduce risk of tissue necrosis, administer the 2 mg/mL solution only
- Inspect infusion site regularly for signs of irritation or vasoconstriction
- extravasation may cause local vasoconstriction leading to tissue necrosis/sloughing
Preparing 2 mg/mL solution
- Preferable for infusion via a peripheral vein
- Take 2.5 mL (100 mg) of dopamine hydrochloride solution and make up to 50 mL with diluent (see Diluents) in a 50 mL syringe
- the diluted solution is stable for 24 hr
- Concentration = 100 mg in 50 mL = 2 mg/mL (2000 microgram/mL)
Preparing 4mg/mL solution
- Infuse via a central line only
- Take 5 mL (200 mg) of dopamine hydrochloride solution and make up to 50 mL with diluent (see Diluents) in a 50 mL syringe
- the diluted solution is stable for 24 hr
- Concentration = 200 mg in 50 mL = 4 mg/mL (4000 microgram/mL)
DOSAGE
- An IV syringe infusion pump is essential for controlling infusion rate
Starting dose
- If patient has been treated with an MAOI (e.g. linezolid, isoniazid, phenelzine, isocarboxazid - see BNF) within the last 2 weeks, start with 0.2 microgram/kg/min
- MAOIs potentiate effects of dopamine and its duration of action
- Otherwise start with 2 microgram/kg/min by continuous IV infusion via as large a vein as possible
- if patients taking MAO-B inhibitors e.g. rasagiline, or standard doses of selegiline, do not reduce dose of dopamine
Rate change
- Monitor heart rate and rhythm, BP, cardiac output (if possible), and urine output
- if no response, seek advice of cardiology before increasing dose further
- Increase rate at 0.5 microgram/kg/min every 30 min according to response, up to 10 microgram/kg/min if required
- dopamine given at rates >5 microgram/kg/min causes vasoconstriction, which can reduce renal perfusion and worsen heart failure
50mL syringe of 2 mg/mL solution
Flow rate (mL/hr) for dopamine hydrochloride infusion (2 mg/mL)
Dosage microgram/ kg/min | Weight (kg) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 | 85 | 90 | 95 | 100 | |
0.5 | 0.7 | 0.8 | 0.8 | 0.9 | 1.0 | 1.1 | 1.1 | 1.2 | 1.3 | 1.4 | 1.4 | 1.5 |
1 | 1.4 | 1.5 | 1.7 | 1.8 | 2.0 | 2.1 | 2.3 | 2.4 | 2.6 | 2.7 | 2.9 | 3.0 |
1.5 | 2.0 | 2.3 | 2.5 | 2.7 | 2.9 | 3.2 | 3.4 | 3.6 | 3.8 | 4.1 | 4.3 | 4.5 |
2 | 2.7 | 3.0 | 3.3 | 3.6 | 3.9 | 4.2 | 4.5 | 4.8 | 5.1 | 5.4 | 5.7 | 6.0 |
2.5 | 3.4 | 3.8 | 4.1 | 4.5 | 4.9 | 5.3 | 5.6 | 6.0 | 6.4 | 6.8 | 7.1 | 7.5 |
3 | 4.1 | 4.5 | 5.0 | 5.4 | 5.9 | 6.3 | 6.8 | 7.2 | 7.7 | 8.1 | 8.6 | 9.0 |
3.5 | 4.7 | 5.3 | 5.8 | 6.3 | 6.8 | 7.4 | 7.9 | 8.4 | 8.9 | 9.5 | 10.0 | 10.5 |
4 | 5.4 | 6.0 | 6.6 | 7.2 | 7.8 | 8.4 | 9.0 | 9.6 | 10.2 | 10.8 | 11.4 | 12.0 |
4.5 | 6.1 | 6.8 | 7.4 | 8.1 | 8.8 | 9.5 | 10.1 | 10.8 | 11.5 | 12.2 | 12.8 | 13.5 |
5 | 6.8 | 7.5 | 8.3 | 9.0 | 9.8 | 10.5 | 11.3 | 12.0 | 12.8 | 13.5 | 14.3 | 15.0 |
7.5 | 10.1 | 11.3 | 12.4 | 13.5 | 14.6 | 15.8 | 16.9 | 18.0 | 19.1 | 20.2 | 21.4 | 22.5 |
10 | 13.5 | 15.0 | 16.5 | 18.0 | 19.5 | 21.0 | 22.5 | 24.0 | 25.5 | 27.0 | 28.5 | 30.0 |
50mL syringe of 4 mg/mL solution
- Give ONLY through a central line
Flow rate (mL/hr) for dopamine hydrochloride infusion (4 mg/mL)
Dosage microgram/ kg/min | Weight (kg) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
45 | 50 | 55 | 60 | 65 | 70 | 75 | 80 | 85 | 90 | 95 | 100 | |
0.5 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 |
1 | 0.7 | 0.8 | 0.8 | 0.9 | 1.0 | 1.1 | 1.1 | 1.2 | 1.3 | 1.4 | 1.4 | 1.5 |
1.5 | 1.0 | 1.1 | 1.2 | 1.4 | 1.5 | 1.6 | 1.7 | 1.8 | 1.9 | 2.0 | 2.1 | 2.3 |
2 | 1.4 | 1.5 | 1.7 | 1.8 | 2.0 | 2.1 | 2.3 | 2.4 | 2.6 | 2.7 | 2.9 | 3.0 |
2.5 | 1.7 | 1.9 | 2.1 | 2.3 | 2.4 | 2.6 | 2.8 | 3.0 | 3.2 | 3.4 | 3.6 | 3.8 |
3 | 2.0 | 2.3 | 2.5 | 2.7 | 2.9 | 3.2 | 3.4 | 3.6 | 3.8 | 4.1 | 4.3 | 4.5 |
3.5 | 2.4 | 2.6 | 2.9 | 3.2 | 3.4 | 3.7 | 3.9 | 4.2 | 4.5 | 4.7 | 5.0 | 5.3 |
4 | 2.7 | 3.0 | 3.3 | 3.6 | 3.9 | 4.2 | 4.5 | 4.8 | 5.1 | 5.4 | 5.7 | 6.0 |
4.5 | 3.0 | 3.4 | 3.7 | 4.1 | 4.4 | 4.7 | 5.1 | 5.4 | 5.7 | 6.1 | 6.4 | 6.8 |
5 | 3.4 | 3.8 | 4.1 | 4.5 | 4.9 | 5.3 | 5.6 | 6.0 | 6.4 | 6.8 | 7.1 | 7.5 |
7.5 | 5.1 | 5.6 | 6.2 | 6.8 | 7.3 | 7.9 | 8.4 | 9.0 | 9.6 | 10.1 | 10.7 | 11.3 |
10 | 6.8 | 7.5 | 8.3 | 9.0 | 9.8 | 10.5 | 11.3 | 12.0 | 12.8 | 13.5 | 14.3 | 15.0 |
WITHDRAWAL
- Withdraw dopamine gradually, monitoring for hypotension